TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28133708
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg on-demand tadalafil (OD-TAD)
Study: 28133708
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg daily tadalafil (OAD-TAD)
Study: 21816087
Drug: Presumptive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Presumptive treatment for all
Study: 12610183
Drug: Cyclophosphamide (C;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide (C; 75 mg/m(2) orally days 1 to 14), epirubicin (E; 60 mg/m(2) IV days 1, 8), and fluorouracil (F; 500 mg/m(2) IV days 1, 8) - CEF arm
Study: 12610183
Drug: Epirubicin (E;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin (E; 120 mg/m(2) IV day 1), Cyclophosphamide (C; 830 mg/m(2) IV day 1), and filgrastim (5 micro g/kg/d subcutaneously days 2 to 13) - EC arm
Study: 23998433
Drug: Oral paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral paracetamol (1 g) plus intravenous ketorolac (30 mg i.v. once daily)
Study: 23998433
Drug: Intravenous ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ketorolac (30 mg i.v. once daily) alone
Study: 21558299
Drug: ACT measured
Normalized name: ACT-101
DrugBank: ACT-101 (DB17000)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACT measured at 1 min after heparin injection
Study: 21558299
Drug: ACT measured
Normalized name: ACT-101
DrugBank: ACT-101 (DB17000)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACT measured at 2 min after heparin injection
Study: 21558299
Drug: ACT measured
Normalized name: ACT-101
DrugBank: ACT-101 (DB17000)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACT measured at 3 min after heparin injection
Study: 21558299
Drug: ACT measured
Normalized name: ACT-101
DrugBank: ACT-101 (DB17000)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACT measured at 4 min after heparin injection
Study: 21558299
Drug: ACT measured
Normalized name: ACT-101
DrugBank: ACT-101 (DB17000)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACT measured at 5 min after heparin injection
Study: 19746676
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg drospirenone plus 20 microg ethinylestradiol (24/4 regimen)
Study: 11435053
Drug: 30 ppm
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 ppm inhaled nitric oxide
Study: 8037411
Drug: Sulindac and
Normalized name: Sulindac
DrugBank: Sulindac (DB00605)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sulindac and Aspirin
Study: 30477915
Drug: Control (intracytoplasmic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (intracytoplasmic sperm injection)
Study: 21698991
Drug: Oral health
Normalized name: CETYLPYRIDINIUM CHLORIDE 0.07 g in 100 mL ORAL RINSE [Assured Oral Health Fresh Mint]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral health education (OHE) every 3 months
Study: 9049584
Drug: Oral fluconazole
Normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral fluconazole 400 mg
Study: 9049584
Drug: Intravenous fluconazole
Normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous fluconazole 400 mg
Study: 8349330
Drug: Fish or
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish or fish oil supplements (6 or 12 fish-oil capsules daily, fish meals providing 1.3 g of eicosapentaenoic acid, or a combination of fish oil and fish)
Study: 2939691
Drug: Zimeldine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zimeldine (100 mg b.i.d.)
Study: 27356143
Drug: Topical insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical insulin (1 U/cm2 wound area), applied twice daily for 7 days.
Study: 27356143
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline dressing (control group), applied twice daily for 7 days.
Study: 19076574
Drug: Nerve block
Normalized name: Nerve Block Tray 22g
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nerve block of the auricular branch of the Vagus (Nerve of Arnold) with 0.2 ml of 0.25% bupivacaine
Study: 19076574
Drug: Intranasal fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intranasal fentanyl 2 mcg.kg(‐1)
Study: 16115360
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (providing 2.7 g/d EPA and DHA) plus antioxidants (vitamins A, C and E, and Se)
Study: 11990448
Drug: Methods to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methods to modulate the host response in periodontal therapy
Study: 7486080
Drug: Procaine hydrochloride
Normalized name: Procaine Hydrochloride
DrugBank: Procaine (DB00721)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Procaine hydrochloride (1 mM) added to St. Thomas' Hospital cardioplegic solution II (Plegisol)
Study: 7486080
Drug: Saline added
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline added to St. Thomas' Hospital cardioplegic solution II (Plegisol)
Study: 2119786
Drug: Oral-aural group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral-aural group
Study: 17521302
Drug: Antiplatelet drug
Normalized name: simethicone
DrugBank: Simethicone (DB09512)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiplatelet drug users
Study: 17521302
Drug: Non-users of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-users of antiplatelet drugs
Study: 11410112
Drug: High-dose GIK
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose GIK
Study: 9429742
Drug: Letrozole 2.5
Normalized name: letrozole 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letrozole 2.5 mg orally (p.o.)
Study: 9429742
Drug: Letrozole 2.5
Normalized name: letrozole 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letrozole 2.5 mg intravenously (i.v.)
Study: 9429742
Drug: Letrozole 2.5
Normalized name: letrozole 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letrozole 2.5 mg orally (p.o.) and intravenously (i.v.)
Study: 8220938
Drug: Maxepa (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maxepa (10 capsules per day for 12 months)
Study: 8220938
Drug: Placebo (air-filled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (air-filled capsules, 10 per day for 12 months)
Study: 3629186
Drug: Intravenous cholecystokinin
Normalized name: cholecystokinin
DrugBank: Cholecystokinin (DB08862)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous cholecystokinin (CCK)
Study: 3629186
Drug: Oral bile
Normalized name: bile salts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral bile acid load of 500 mg chenodeoxycholic acid (CDA)
Study: 24473926
Drug: Psychological treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychological treatments for PTSD
Study: 22942337
Drug: β-blocker (BB)
Normalized name: capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: β-blocker (BB)
Study: 16814412
Drug: 17beta-estradiol (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17beta-estradiol (1 mg)
Study: 15591730
Drug: Prescription of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescription of fluoride lozenges
Study: 12405170
Drug: Iron supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron supplementation at a dose of 2 mg/kg/day
Study: 12405170
Drug: Iron supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron supplementation at a dose of 2 mg/kg/every other day
Study: 12405170
Drug: Iron supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron supplementation at a dose of 1 mg/kg/day
Study: 6994301
Drug: Single-morning daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-morning daily prednisone treatment
Study: 6994301
Drug: Alternate-day prednisone
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alternate-day prednisone treatment
Study: 28490674
Drug: Liquid oil
Normalized name: castor oil Oral Liquid Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid oil (22.25 g coconut oil or sunflower oil)
Study: 28490674
Drug: Oleogel (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oleogel (25 g coconut oleogel or sunflower oleogel)
Study: 22432725
Drug: Flax seed
Normalized name: FLAX SEED
DrugBank: Flax seed (DB10708)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flax seed powder (10 g daily for 1 month)
Study: 17588299
Drug: etoricoxib 120
Normalized name: etoricoxib 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: etoricoxib 120 mg once daily
Study: 17588299
Drug: indomethacin 50
Normalized name: indomethacin 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: indomethacin 50 mg three times daily
Study: 11451727
Drug: Bread with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bread with 1.2 mg Zn and 17 microg folic acid (A)
Study: 11451727
Drug: Bread with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bread with 1.2 mg Zn and 144 microg folic acid (B)
Study: 11451727
Drug: Bread with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bread with 3.0 mg Zn and 17 microg folic acid (C)
Study: 11451727
Drug: Bread with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bread with 2.9 mg Zn and 144 microg folic acid (D)
Study: 7752830
Drug: Simvastatin 20
Normalized name: simvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 20 mg plus CoQ10 100 mg
Study: 22574377
Drug: Yimusake 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yimusake 1 tablet (50 mg) per day for 4 weeks
Study: 22574377
Drug: Trazodone hydrochloride
Normalized name: Trazodone Hydrochloride
DrugBank: Trazodone (DB00656)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Trazodone hydrochloride 1 tablet (50 mg) per day for 4 weeks
Study: 17686104
Drug: Steroid treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid treatment or allergen provocation
Study: 9013366
Drug: rHu GM‐CSF
Approvals — FDA: no, EMA: no, PMDA: no
Description: rHu GM‐CSF (5 micrograms/kg subcutaneously daily for 4 days)
Study: 9013366
Drug: rHu GM‐CSF
Approvals — FDA: no, EMA: no, PMDA: no
Description: rHu GM‐CSF after the first dose
Study: 9013366
Drug: Zidovudine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zidovudine (200 mg orally every 8 hours)
Study: 23923597
Drug: Routine drug
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine drug treatment (control group)
Study: 17464552
Drug: Hydration supplementation
Normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydration supplementation (1500 ml of water + 1500 mg of NaCl/day)
Study: 7909999
Drug: Topical levocabastine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical levocabastine (eye drops and nasal spray)
Study: 3299678
Drug: Propranolol (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (10 mg intravenously twice daily) + Neostigmine (0.5 mg subcutaneously twice daily)
Study: 3299678
Drug: Neostigmine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neostigmine (0.5 mg subcutaneously twice daily)
Study: 20843456
Drug: Pelvic floor
Normalized name: Tenscare Kegel Toner Pelvic Floor Trainer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pelvic floor exercises (16 sessions, twice a week for 30 minutes)
Study: 18164521
Drug: Preventive AIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preventive AIDS vaccine
Study: 10590282
Drug: Imipenem/cilastatin 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipenem/cilastatin 1 g iv three-times daily
Study: 7797060
Drug: Inhaled beta
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled beta 2-agonists
Study: 2194992
Drug: Amitriptyline (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline (150 mg/day)
Study: 2194992
Drug: Amitrypylinoxide (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitrypylinoxide (150 mg/day)
Study: 29450728
Drug: 20 µg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 µg/day of vitamin D3
Study: 29572676
Drug: 10 µg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 µg/day of vitamin D3
Study: 25820474
Drug: Eicosapentaenoic acid
Normalized name: eicosapentaenoic acid
DrugBank: Icosapent (DB00159)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eicosapentaenoic acid (EPA) 1.3 g/day
Study: 25820474
Drug: α-lipoic acid
Normalized name: α-lipoic acid
DrugBank: Lipoic acid (DB00166)
Approvals — FDA: no, EMA: no, PMDA: no
Description: α-lipoic acid 0.3 g/day
Study: 25820474
Drug: Both EPA
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both EPA (1.3 g/day) and α-lipoic acid (0.3 g/day)
Study: 24059443
Drug: Interactive Metronome
Normalized name: Menin-mll interaction inhibitor ko 539
DrugBank: Ziftomenib (DB17171)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interactive Metronome (IM) therapy
Study: 16832589
Drug: Medication (MED)
Normalized name: Medicated Shampoo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication (MED) - extended release oxybutynin at 5 mg/day for 3 months
Study: 15516392
Drug: Oxytocin bolus
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxytocin bolus dose
Study: 31551154
Drug: Cytokine enrichment
Normalized name: cytosine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytokine enrichment of culture medium (granulocyte‐macrophage colony‐stimulating factor, heparin‐binding epidermal growth factor‐like growth factor, and leukemia inhibitory factor)
Study: 28669793
Drug: 5% methylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% methylene blue mediated photodynamic therapy using Fotosan device for 30s (630nm wavelength and 7.2‐14.4J/cm2 dose) for 4 sessions
Study: 28669793
Drug: 0.5mg tab
Normalized name: DIGOXIN 0.5MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5mg tab dexamethasone solution in 5cc water, rinsed 4 times a day for two weeks
Study: 26134837
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (standard hypertension treatment recommendations)
Study: 23786760
Drug: Etanercept 2
Normalized name: etanercept 25 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept 2 × 25 mg s.c./week
Study: 16835670
Drug: Nurse-centred surveillance
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nurse-centred surveillance and treatment
Study: 16835670
Drug: Combined endpoint
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined endpoint (LDL-C < 2.5 mmol/L, triglycerides < 2.0 mmol/L, total cholesterol/HDL < 4.0)
Study: 15074086
Drug: Naoreqing oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naoreqing oral liquid (NRQ)
Study: 15074086
Drug: Naoreqing oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naoreqing oral liquid (NRQ) plus western medicine (WM)
Study: 10732177
Drug: Routine conventional
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine conventional therapy
Study: 8882986
Drug: CT plus
Normalized name: Protect Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: CT plus IFN alpha‐2a (3 MU/m2 twice weekly)
Study: 2408735
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy with methotrexate, bleomycin, and cisplatin
Study: 3324523
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g single dose of amoxicillin
Study: 3324523
Drug: 4-day course
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-day course of 3 doses of 750 mg amoxicillin
Study: 23782128
Drug: Extended-release methylphenidate
Normalized name: methylphenidate Extended Release Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release methylphenidate (MPH)
Study: 18423697
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg dutasteride
Study: 18423697
Drug: 5alpha-reductase inhibitors
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5alpha-reductase inhibitors (dutasteride and finasteride)
Study: 9199074
Drug: Enoxaparin 1
Normalized name: ENOXAPARIN 100MG/ML INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin 1 x 40 mg per day
Study: 9199074
Drug: Na-heparin 3
Normalized name: Heparin Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Na-heparin 3 x 5000 IE (increased to 3 x 7500 IE if PTT did not reach 40 seconds)
Study: 28687281
Drug: Peak NSE
Normalized name: PEAK FLOW METER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peak NSE >38ng/l
Study: 28687281
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of peak NSE >38ng/l and generalised oedema on CT
Study: 23588803
Drug: Recent developments
Normalized name: petrolatum
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recent developments (sensory discrimination training, mirror treatment, graded motor imagery, prosthesis training, training in virtual reality)
Study: 17342992
Drug: Compound Shenhua
Normalized name: BENZOIN COMPOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compound Shenhua Tablet (SHT)
Study: 14990014
Drug: Propranolol 10-20
Normalized name: propranolol 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 10-20 mg orally three times a day for 7 days
Study: 14990014
Drug: Octreotide 0.05
Normalized name: octreotide 0.05 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide 0.05 mg subcutaneously two times a day for 3 days
Study: 14990014
Drug: Octreotide 0.1
Normalized name: octreotide 0.1 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide 0.1 mg subcutaneously two times a day for 3 days
Study: 11772796
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of midazolam (M group)
Study: 2649317
Drug: buspirone (24.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: buspirone (24.5 mg daily)
Study: 2649317
Drug: diazepam (20.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: diazepam (20.8 mg daily, range 10 mg to 60 mg)
Study: 715070
Drug: Vaginal suppositories
Normalized name: Miconazole Nitrate Vaginal Suppositories
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal suppositories of 15(S)15 methyl prostaglandin F2 alpha methyl ester (50 cases)
Study: 29045302
Drug: Pregnenolone (add-on
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregnenolone (add-on treatment)
Study: 17139034
Drug: Adherence therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adherence therapy
Study: 17941026
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of liposomal amphotericin B (AmB) at 3 mg/kg daily and caspofungin at standard dose
Study: 17941026
Drug: High-dose monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose monotherapy with liposomal amphotericin B at 10 mg/kg daily
Study: 11564124
Drug: Levetiracetam (1,000-3,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levetiracetam (1,000-3,000 mg/day)
Study: 9636808
Drug: Sublingual-swallow immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual-swallow immunotherapy (SLIT) with standardized grass-pollen extract
Study: 7868848
Drug: Oral tacrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tacrine (25 and 50 mg b.i.d.)
Study: 7868848
Drug: Rectal tacrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal tacrine (12.5 and 25 mg b.i.d.)
Study: 7868848
Drug: Rectal tacrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal tacrine
Study: 7868848
Drug: Oral tacrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tacrine
Study: 26507186
Drug: Sufficient vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufficient vitamin D levels (>30 ng/ml)
Study: 26507186
Drug: Insufficient vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insufficient vitamin D (<30 ng/ml)
Study: 26507186
Drug: Deficient vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deficient vitamin D (<20 ng/ml)
Study: 26507186
Drug: Each 1
Normalized name: ClindaReach 1% Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each 1 ng/ml increase in 25(OH)D
Study: 20849470
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg controlled-release levodopa/carbidopa
Study: 20849470
Drug: Off-state (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Off-state (no treatment)
Study: 16467101
Drug: Dendritic cell-MFP
Normalized name: Dendritic cells vaccine
DrugBank: Dendritic cells vaccine (DB15803)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dendritic cell-MFP therapy
Study: 9359722
Drug: Clarithromycin plus
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clarithromycin plus clofazimine plus ethambutol (three-drug arm)
Study: 9359722
Drug: Clarithromycin plus
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clarithromycin plus clofazimine (two-drug arm)
Study: 7994648
Drug: Oral Vit
Normalized name: vitamin A Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Vit B2 5mg three times a day during phototherapy
Study: 2657838
Drug: Buspirone (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buspirone (15 mg/day, flexible to 30 mg/day, mean daily dose 20.5 mg)
Study: 820622
Drug: TRH injection
DrugBank: Protirelin (DB09421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TRH injection
Study: 31438912
Drug: Housing First
Approvals — FDA: no, EMA: no, PMDA: no
Description: Housing First with Assertive Community Treatment (HF with ACT)
Study: 22043463
Drug: Open flap
Normalized name: BOTTLE OPENER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open flap implant placement
Study: 7857222
Drug: Subcutaneous recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous recombinant growth hormone (rGH) 0.2 iu/kg daily for 7 days
Study: 7857222
Drug: Placebo (saline)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (saline) injection daily for 7 days
Study: 2034244
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy (cisplatin and fluorouracil) followed by radiation therapy
Study: 1469466
Drug: Surgery followed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Surgery followed by radiation therapy
Study: 16435478
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment for duodenal ulcer